We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trading to commence on Nasdaq on Oct. 29, 2021, under the ticker symbol BTTX Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy...
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) (the “Company”), a publicly traded special purpose acquisition company, announced today that in a...
NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD, “Mountain Crest II”), a publicly-traded special purpose acquisition company and...
Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases...
Pivotal trial of BT-001 in type 2 diabetes expected to be fully enrolled in Q4 2021, with primary endpoint readout in Q1 2022; de novo submission to FDA requesting marketing authorization planned...
Open-label, real-world study will evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at the root cause of type 2 diabetes Study to evaluate the durability of treatment...
Open-label, non-randomized, controlled study will span one year and evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at root cause of type 2 diabetes Study to evaluate...
Transaction values Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100% of their equity...
New York, N.Y., March 15, 2021 (GLOBE NEWSWIRE) -- March 15, 2021 Mountain Crest Acquisition Corp. II (the “Company”) (NASDAQ: MCADU), a blank check company formed for the purpose of entering...
New York, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCADU, the “Company”) announced today that the underwriters in its initial public offering, pursuant to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions